ARTICLE | Clinical News
FDA approves traveler's diarrhea drug from Cosmo
November 30, 2018 8:34 PM UTC
FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of Escherichia coli.
The company said it will launch the drug next quarter. ...
BCIQ Company Profiles